Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs

被引：6

作者：

Tawaratsumida H. ^{[1
]}

Setoguchi T. ^{[2
]}

Arishima Y. ^{[1
]}

Ohtsubo H. ^{[3
]}

Akimoto M. ^{[4
]}

Ishidou Y. ^{[5
]}

Nagano S. ^{[1
]}

Taketomi E. ^{[1
,6
]}

Sunahara N. ^{[1
,6
]}

Komiya S. ^{[1
]}

机构：

[1] Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima

[2] Near-Future Locomotor Organ Medicine Creation Course (Kusunoki Kai), Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima

[3] Center for Rheumatic Diseases, Japanese Red Cross Kagoshima Hospital, Kagoshima

[4] Department of Hematology and Immunology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima

[5] Department of Medical Joint Materials, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima

[6] Department of Orthopaedic Surgery, Japanese Red Cross Kagoshima Hospital, Kagoshima

来源：

BMC Research Notes | / 10卷 / 1期

关键词：

Biological disease-modifying anti-rheumatic drugs (bDMARDs); Osteoporosis; Rheumatoid arthritis (RA); Risk factors;

D O I：

10.1186/s13104-017-3086-7

中图分类号：

学科分类号：

摘要：

Objective: Osteoporosis is a complication of rheumatoid arthritis. We examined the risk factors for bone loss in rheumatoid arthritis patients receiving biological disease-modifying anti-rheumatic drugs. Lumbar spine and femoral neck bone mineral density was measured at two time points in 153 patients with rheumatoid arthritis managed with biological disease-modifying anti-rheumatic drugs. We examined patients' variables to identify risk factors for least significant reduction of bone mineral density. Results: Least significant reduction of lumbar spine bone mineral density (≤ - 2.4%) was seen in 13.1% of patients. Least significant reduction of femoral neck bone mineral density (≤ - 1.9%) was seen in 34.0% of patients. Multiple logistic regression analysis showed that a risk factor for least significant reduction of the lumbar spine was high-dose methylprednisolone use. Multiple regression analysis showed that a risk factor for least significant reduction of the femoral neck was short disease duration. Our findings showed that a risk factor for femoral neck bone mineral density reduction was a short disease duration. These findings suggest that rheumatoid arthritis patients receiving treatment with biological disease-modifying anti-rheumatic drugs may benefit from earlier osteoporosis treatments to prevent femoral neck bone loss. © 2017 The Author(s).

引用

共 35 条

[1] Lodder M.C., Haugeberg G., Lems W.F., Uhlig T., Orstavik R.E., Kostense P.J., Dijkmans B.A., Kvien T.K., Woolf A.D., Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: The Oslo-Truro-Amsterdam (OSTRA) collaborative study, Arthritis Rheum, 49, 2, pp. 209-215, (2003)
[2] Haugeberg G., Uhlig T., Falch J.A., Halse J.I., Kvien T.K., Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: Results from 394 patients in the Oslo County Rheumatoid Arthritis register, Arthritis Rheum, 43, 3, pp. 522-530, (2000)
[3] Dimitroulas T., Nikas S.N., Trontzas P., Kitas G.D., Biologic therapies and systemic bone loss in rheumatoid arthritis, Autoimmun Rev, 12, 10, pp. 958-966, (2013)
[4] Emery P., Dorner T., Optimising treatment in rheumatoid arthritis: A review of potential biological markers of response, Ann Rheum Dis, 70, 12, pp. 2063-2070, (2011)
[5] Venkateshan S.P., Sidhu S., Malhotra S., Pandhi P., Efficacy of biologicals in the treatment of rheumatoid arthritis. A meta-analysis, Pharmacology, 83, 1, pp. 1-9, (2009)
[6] Keystone E., Recent concepts in the inhibition of radiographic progression with biologics, Curr Opin Rheumatol, 21, 3, pp. 231-237, (2009)
[7] Sakthiswary R., Das S., The effects of TNF alpha antagonist therapy on bone metabolism in rheumatoid arthritis: A systematic review, Curr Drug Targets, 14, 13, pp. 1552-1557, (2013)
[8] Roussy J.P., Bessette L., Bernatsky S., Rahme E., Lachaine J., Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over, Osteoporos Int, 24, 9, pp. 2483-2492, (2013)
[9] Kawai V.K., Grijalva C.G., Arbogast P.G., Curtis J.R., Solomon D.H., Delzell E., Chen L., Ouellet-Hellstrom R., Herrinton L., Liu L., Et al., Initiation of tumor necrosis factor alpha antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases, Arthritis Care Res, 65, 7, pp. 1085-1094, (2013)
[10] Confavreux C.B., Chapurlat R.D., Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis, Osteoporos Int, 22, 4, pp. 1023-1036, (2011)

← 1 2 3 4 →